Total Payments
$134,790
2024 Payments
$19,856
Companies
19
Transactions
118
Medicare Patients
6,481
Medicare Billing
$616,260
Payment Breakdown by Category
Consulting$111,678 (82.9%)
Research$9,613 (7.1%)
Travel$6,812 (5.1%)
Other$3,190 (2.4%)
Food & Beverage$2,919 (2.2%)
Education$578.87 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $111,678 | 44 | 82.9% |
| Unspecified | $9,613 | 6 | 7.1% |
| Travel and Lodging | $6,812 | 26 | 5.1% |
| Food and Beverage | $2,919 | 30 | 2.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,640 | 3 | 2.0% |
| Education | $578.87 | 8 | 0.4% |
| Honoraria | $550.00 | 1 | 0.4% |
Payments by Type
General
$125,177
112 transactions
Research
$9,613
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $22,364 | 10 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $19,954 | 9 | $0 (2024) |
| Kyowa Kirin, Inc. | $14,523 | 15 | $0 (2024) |
| Janssen Global Services, LLC | $13,546 | 10 | $0 (2024) |
| PFIZER INC. | $11,715 | 15 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $9,194 | 12 | $0 (2024) |
| ARGENX US, INC. | $8,189 | 4 | $0 (2023) |
| Mallinckrodt Hospital Products Inc. | $7,539 | 9 | $0 (2024) |
| UCB, Inc. | $6,797 | 8 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $5,673 | 11 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $19,856 | 28 | Mallinckrodt Hospital Products Inc. ($7,539) |
| 2023 | $39,254 | 22 | Boehringer Ingelheim International GmbH ($15,457) |
| 2022 | $32,028 | 25 | Incyte Corporation ($22,325) |
| 2021 | $2,174 | 3 | GENZYME CORPORATION ($1,124) |
| 2020 | $16,370 | 7 | Kyowa Kirin, Inc. ($9,300) |
| 2019 | $5,859 | 12 | Kyowa Kirin, Inc. ($5,107) |
| 2018 | $8,852 | 13 | UCB, Inc. ($6,797) |
| 2017 | $10,398 | 8 | Regeneron Pharmaceuticals, Inc. ($6,038) |
All Payment Transactions
118 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Therakos Healthcare LLC | CELLEX (Device) | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| Category: CRITICAL CARE | ||||||
| 12/12/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $410.16 | Research |
| Study: A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) • Category: ONCOLOGY | ||||||
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $303.97 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $67.77 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $47.71 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $35.62 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $32.99 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/20/2024 | Mallinckrodt Hospital Products Inc. | CELLEX (Device) | Consulting Fee | Cash or cash equivalent | $1,625.00 | General |
| Category: CRITICAL CARE | ||||||
| 11/11/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | — | Food and Beverage | In-kind items and services | $61.68 | General |
| 11/06/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $39.47 | General |
| Category: Dermatology | ||||||
| 11/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $427.34 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $35.25 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/30/2024 | Mallinckrodt Hospital Products Inc. | CELLEX (Device) | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| Category: CRITICAL CARE | ||||||
| 10/08/2024 | Mallinckrodt Hospital Products Inc. | UVADEX (Drug) | Education | In-kind items and services | $10.60 | General |
| Category: CRITICAL CARE | ||||||
| 10/08/2024 | Mallinckrodt Hospital Products Inc. | UVADEX (Drug) | Education | In-kind items and services | $10.60 | General |
| Category: CRITICAL CARE | ||||||
| 10/08/2024 | Mallinckrodt Hospital Products Inc. | UVADEX (Drug) | Education | In-kind items and services | $10.60 | General |
| Category: CRITICAL CARE | ||||||
| 10/08/2024 | Mallinckrodt Hospital Products Inc. | UVADEX (Drug) | Education | In-kind items and services | $10.60 | General |
| Category: CRITICAL CARE | ||||||
| 10/08/2024 | Mallinckrodt Hospital Products Inc. | UVADEX (Drug) | Education | In-kind items and services | $10.60 | General |
| Category: CRITICAL CARE | ||||||
| 10/08/2024 | Mallinckrodt Hospital Products Inc. | UVADEX (Drug) | Education | In-kind items and services | $10.60 | General |
| Category: CRITICAL CARE | ||||||
| 09/26/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | — | Food and Beverage | In-kind items and services | $25.15 | General |
| 08/05/2024 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| 03/19/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $3,937.50 | General |
| 03/19/2024 | Boehringer Ingelheim International GmbH | — | Travel and Lodging | In-kind items and services | $463.65 | General |
| 03/19/2024 | Boehringer Ingelheim International GmbH | — | Travel and Lodging | In-kind items and services | $96.36 | General |
| 03/09/2024 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Monoclonal Antibody | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| BREPOCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| PF07038124 BREPOCITINIB DAZUKIBART PF06763809 DEKAVIL PF06817024 PF06480605 RITLECITINIB ZIMLOVISERTIB PF06826647 PF06835375 MULTI PRODUCT PF07054894 PF06473871 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID | Regeneron Pharmaceuticals, Inc. | $1,533 | 1 |
| ZIMLOVISERTIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | Regeneron Pharmaceuticals, Inc. | $410.16 | 1 |
| RITLECITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 25 | 1,460 | 2,562 | $647,756 | $146,324 |
| 2022 | 23 | 1,547 | 2,906 | $636,143 | $148,892 |
| 2021 | 24 | 1,639 | 3,021 | $314,454 | $174,350 |
| 2020 | 29 | 1,835 | 6,386 | $296,202 | $146,694 |
Total Patients
6,481
Total Services
14,875
Medicare Billing
$616,260
Procedure Codes
101
All Medicare Procedures & Services
101 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 341 | 652 | $218,420 | $59,100 | 27.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 180 | 219 | $50,370 | $13,748 | 27.3% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 98 | 107 | $46,010 | $9,825 | 21.4% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2023 | 22 | 34 | $41,406 | $9,765 | 23.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 82 | 82 | $44,690 | $9,496 | 21.2% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 74 | 81 | $29,574 | $5,696 | 19.3% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 135 | 157 | $33,188 | $5,590 | 16.8% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 58 | 97 | $17,296 | $3,744 | 21.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 58 | 59 | $19,013 | $3,558 | 18.7% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 19 | 37 | $20,400 | $3,526 | 17.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 26 | $13,650 | $3,226 | 23.6% |
| 96900 | Application of ultraviolet light to skin | Office | 2023 | 21 | 166 | $15,272 | $2,877 | 18.8% |
| 96567 | Application of light to destroy precancer skin growth | Office | 2023 | 22 | 24 | $14,496 | $2,613 | 18.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $11,760 | $2,469 | 21.0% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 90 | 410 | $18,860 | $2,029 | 10.8% |
| 96405 | Administration of chemotherapy into growth, 1-7 | Office | 2023 | 14 | 33 | $12,462 | $1,928 | 15.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 25 | 25 | $9,000 | $1,687 | 18.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 30 | 32 | $5,376 | $1,305 | 24.3% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 23 | 31 | $5,270 | $1,219 | 23.1% |
| 17261 | Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | Office | 2023 | 12 | 14 | $5,500 | $1,157 | 21.0% |
| 11105 | Punch biopsy, each additional skin growth | Office | 2023 | 20 | 24 | $4,800 | $1,112 | 23.2% |
| 99451 | Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | Facility | 2023 | 11 | 11 | $1,155 | $305.14 | 26.4% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 63 | 175 | $5,200 | $141.97 | 2.7% |
| 99421 | Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | Office | 2023 | 12 | 12 | $300.00 | $138.84 | 46.3% |
| J9260 | Methotrexate sodium, 50 mg | Office | 2023 | 15 | 38 | $4,289 | $67.92 | 1.6% |
About Dr. Aaron Mangold, M.D
Dr. Aaron Mangold, M.D is a Dermatology healthcare provider based in Scottsdale, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/01/2011. The National Provider Identifier (NPI) number assigned to this provider is 1376832196.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Aaron Mangold, M.D has received a total of $134,790 in payments from pharmaceutical and medical device companies, with $19,856 received in 2024. These payments were reported across 118 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($111,678).
As a Medicare-enrolled provider, Mangold has provided services to 6,481 Medicare beneficiaries, totaling 14,875 services with total Medicare billing of $616,260. Data is available for 4 years (2020–2023), covering 101 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Scottsdale, AZ
- Active Since 04/01/2011
- Last Updated 09/08/2020
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1376832196
Products in Payments
- SANCUSO (Drug) $9,300
- CELLEX (Device) $8,775
- VYVGART (Drug) $6,314
- DUPIXENT DUPILUMAB INJECTION (Biological) $6,235
- POTELIGEO (Drug) $5,142
- Rituxan (Biological) $4,278
- Cimzia (Drug) $3,690
- DUPIXENT (Biological) $3,607
- LITFULO (Drug) $3,200
- OFEV (Drug) $3,125
- LIBTAYO (Biological) $2,135
- Poteligeo (Drug) $80.78
- UVADEX (Drug) $63.60
- OPZELURA (Drug) $39.47
- CIBINQO (Drug) $15.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Scottsdale
Dr. Anthony Nuara, M.d., Ph.d, M.D., PH.D
Dermatology — Payments: $442,438
Dermatology $442,438
Karan Lal, Do, DO
Dermatology — Payments: $369,378
Dermatology $369,378
Matthew Laffer, D.o, D.O
Dermatology — Payments: $141,722
Dermatology $141,722
Ms. Brenda Latowsky, Md, MD
Dermatology — Payments: $141,122
Dermatology $141,122
Dr. Gary Mccracken, M.d, M.D
Dermatology — Payments: $71,783
Dermatology $71,783
Aleksandar Sekulic, M.d, M.D
Dermatology — Payments: $38,461
Dermatology $38,461